ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1059

Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes

Jonathan Mills1, Gary S. Firestein2 and Brian Pedersen2, 1Rheumatology, University of California, San Diego, San Diego, CA, 2Medicine, University of California San Diego, La Jolla, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, genomics, rheumatoid arthritis (RA) and transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

RA fibroblast-like synoviocytes (FLS) display a unique aggressive phenotype with a distinct epigenetic profile marked by altered chromatin accessibility. We hypothesized that differentially utilized transcription factors (TFs) and/or promoters correlating with open chromatin regions may contribute to RA FLS behavior. We utilized ATAC-sequencing data to compare regions of open chromatin in RA FLS that are the most different when compared to OA. This filter allowed us to identify DNA sequence motifs of TFs most likely to account for RA-specific cell functions.

Methods:

ATAC-seq data from the FLS derived from RA and OA arthroplasty samples and differences corresponding to chromatin accessibility were identified using DiffBind. Loci were filtered for those present in all 11 RA samples but ≤5/10 OA samples or loci present in ≥5 RA samples but in ≤1 OA sample (and vice versa) to identify the extremes of RA-OA differences. These loci were then analyzed for DNA sequence biases using MEME (Multiple EM for Motif Elicitation). Identified motifs were compared to known TFs found in multiple databases using Tomtom. Motifs were identified with high confidence if they corresponded with known patterns in all databases and expressed in FLS.

Results:

Multiple relevant TFs motifs were associated with the extremes of RA-OA chromatin accessibility differences. Motifs for KLF4 and the E2F family of TFs were identified and among the most highly significant. The motif for the E2F family of TFs was identified in 159/575 total sites where chromatin was more open in the RA vs OA samples (MEME e = 1.2e-64, HOCOMOCO q = 2.2e-2). There were 84 genes found within 1000 kb of these 159 sites, and of these, 9 sites were found within gene bodies. RNA-seq was then utilized to identify which genes associated with E2F family binding sites in open chromatin are differentially expressed. Seven of these genes were associated with significant differential expression (CRYBG3, Metazoa_SRP, ANGPTL2, ITGB3, PMP22, GLS and U4; q < 0.05). The motif for the KLF family of TFs was identified in 18/1156 total sites where chromatin was more open in the OA vs RA samples (MEME e = 3.4e-2, TFBSshape q = 0.19). There were 18 genes identified within 1000 kb of these 1156 sites, and of these, 7 sites were found within gene bodies. None of these were differentially expressed.

Conclusion:

Using differences in chromatin access we identified TFs that are associated with neighboring genes with differential expression that distinguish RA from OA. Protein coding genes identified by this approach include proteins involved with cell adhesion that could participate in the pathogenesis of RA.


Disclosure: J. Mills, None; G. S. Firestein, Janssen Pharamceuticals, 2, 5; B. Pedersen, None.

To cite this abstract in AMA style:

Mills J, Firestein GS, Pedersen B. Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/differentially-utilized-transcription-factors-and-enhancers-in-rheumatoid-arthritis-ra-fibroblast-like-synoviocytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differentially-utilized-transcription-factors-and-enhancers-in-rheumatoid-arthritis-ra-fibroblast-like-synoviocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology